Without a new set of tools that clinicians can access at the point of care, the availability of information from QHINs will increase provider burdens because they will struggle to find the information needed to evaluate a patient, take action, complete documentation, and move to the next patient.
Royalty Pharma’s milestone payment from the approval of Pfizer migraine drug Zavzpret stems from financing deals struck with the therapy's previous developer, Biohaven Pharmaceuticals. Royalty Pharma is also in line to receive royalty payments going beyond the next decade.
Some actions to reduce healthcare's carbon footprint actually will save money, said Jonathan Perlin, CEO of the nonprofit national and international accrediting organization.
Georgia policymakers, county officials and the NAACP are asking the federal government to investigate Wellstar Health System’s closure of two Atlanta-area hospitals in predominantly Black neighborhoods. Complaints have recently been filed with the DOJ, IRS and HHS' civil rights office.
Perspectum a company that makes medical imaging devices designed to improve the diagnosis of metabolic diseases and cancer recently announced the second close of its $55 million Series C funding round. Its flagship product is a diagnostic tool that assesses and monitors chronic liver disease.